Cardiovascular risk factors for dementia;Sercowo-naczyniowe czynniki ryzyka otepienia

Psychogeriatria Polska

Volumn 3, Issue 1, 2006, Pages 43-55

  Zabłocki, Krzysztof ^a   Leszek, Jerzy ^b  

^a Specjalistyczny Zespół Psychiatrycznej Opieki Zdrowotnej we Wrocławiu ^*  (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Alzheimer's disease; Cognitive disorders; Dementia; Risk factors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; DEMENTIA; HUMAN; PATHOGENESIS; PROPHYLAXIS; REVIEW; RISK REDUCTION;

EID: 33751044584     PISSN: 17322642     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Starr JM, Halley LJ, Inch S, Shering PA. Blood pressure and cognitive function in healthy old people. J Am Geriatr Soc 1993; 41: 753-756.
2. Seux ML, Thjis L, Forette F, Staessen JA, Birkenhager WH, Bulpitt CJ. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. J Hypertens 1998; 16: 963-969.
3. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20 year follow-up pf 999 men. Hypertension 1998, 31, 780-786.
4. Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A. Cognitive decline in individuals with high blood pressure. Neurology 1999; 53: 1948-1952.
5. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49-55.
6. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: community-based, longitudinal study. Stroke 2003; 34: 594-599.
7. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular factors and risk of dementia in late life. Neurology 2005; 64: 277-281.
8. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L. A 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347: 1141-1145.
9. Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW. Hypertension and the rate of cognitive decline in patients with dementia ofthe Alzheimer type. Alzheimer Dis Assoc Disord 2004; 18: 208-213.
10. Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriat Soc 1996; 44: 411-415.
11. Murray MD, Lane KA, Gao S, Evans RM, Unverzagt FW, Hall KS. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002; 162: 2090-2096.
12. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-817.
13. Starr JM, Deary IJ, Inch S, Cross S, MacLennan WJL. Blood pressure and cognitive decline in healthy old people. J Hum Hypertens 1997; 11: 777-781.
14. Swan GE, Carmelli D, Larue A. Systolic blood pressure tracking over 25 to 30 years and cognitive performance in older adults. Stroke 1998; 29: 2334-2340.
15. Bohannon AD, Fillenbaum GG, Pieper CF, Hanlon JT, Blazer DG. Relationship of race/ethnicity and blood pressure to change in cognitive function. J Am Geriatr Soc 2002; 50: 424-429.
16. Zhu L, Viitanen M, Guo Z, Winblad B, Fratiglioni L. Blood pressure reduction, cardiovascular diseases and cognitive decline in the Mini-Mental State Examination in a community population of normal very old people: a three-year follow-up. J Clin Epidemiol 1998; 51: 385-391.
17. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58: 1640-1646.
18. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH. Cerebral white matter lesions, vascular risk factors and cognitive function in a population based study: the Rotterdam Study. Neurology 1994; 44: 1246-1252.
19. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B. SCOPE study Group. The Study on Cognition and Prognosis in Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
20. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults. BMJ 1996; 312: 801-805.
21. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
22. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Barbarskiene MR. Prevention of dementia in rondomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351.
23. Hanon O, Latour F, Seux ML, Lenoir H, Forette F, Rigaud AS. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French cohort (REAL. FR). J Nutr Health Aging 2005; 9: 106-111.
24. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz M Low blood pressure and the risk of dementia in very old individuals. Neurology 2003; 61: 1667-1672.
25. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S. PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069-1075.
26. Bosch J, Yusuf S, Yogue J, Sleight P, Lonn E, Rangoonwala B. HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomized trial. BMJ 2002; 324: 699-702.
27. Raj N. Kalaria. Vascular Factors in Alzheimer's Disease. International Psychogeriatrics 2003; 15.
28. Gary K Hulse, Nicola T Lantenschlager, Robert J Tait, Osvaldo P Almeida. Dementia Associated with Alcohol and Other Drug Use. International Psychogeriatrics 2005; 17.
29. F Cacciatore, P Abete, D de Santis. Mortality and Blood Pressure in Elderly People with and without Dementia. Gerontology 2005; 51.
30. O Hanon, F Forette. Treatment of Hypertension and Prevention of Dementia. Alzheimer's and Dementia 2005; 1.
31. J Krzytowski. Psychogeriatria. Warszawa: Medyk; 2004.
32. H Wehr, M Bednarska-Makaruk. Czy statyny znajda zastosowanie w leczeniu otepienia? Neurol Neurochir Pol 2005; 39: 318-323.
33. L Medard. Hiperhomocysteinemia czynnikiem ryzyka w patologii ciaży, schorzeniach układu krażenia i chorobie Alzheimera. Med Rodz 1999; 3.
34. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
35. Kivipelto M, Helkala E-L, Hanninen T, Hallikainen M. Midlife vascular risk factors and Alzheimer's disease. BMJ 2001; 322: 1447-1451.
36. Kivipelto M, Helkala E-L, Hanninen T, Hallikainen M. Apo E epsilon allele, elevated midlife total cholesterol level and high midlife systolic blood pressure are independent risk factors for late life Alzheimer disease. Ann Intern Med 2002; 137: 149-55.
37. Diana B Petitti, Valerie C Crooks, J Galen Buckwalter, V Chiu. Blood Pressure Levels Before Dementia. Neurology 2005; 1.
38. Certain blood pressure drugs may slow the deterioration of Alzheimer's disease. News-Medical. Net 2004.
39. Chengxuan Qiu, Bengt Winblad, Johan Fastbom, Laura Fratiglioni. Combined effects of Apo E genotype, blood pressure and antihypertensive drugs use on incident AD. Neurology 2003; 61: 655-660.
40. The latest research on cariovascular risk factors and Alzheimer's disease. Alzheimer's Information Center 2003.
41. Wolozin B, Kellman W, Ruosseau P i wsp. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443.
42. Jick H, Zornberg GL, Jick SS i wsp. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
43. Simons M, Schwarzler F, Lutjohann D. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346-350.
44. Fassbender K, Simons M, Bergmann C i wsp. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-5861.
45. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003; 23: 726-730.
46. Fontbonne A, Berr C, Ducimetire P, Alperovitch A. Changes in Cognitive Abilities Over a 4-Year Period Are Unfavorably Affected in Elderly Diabetic Subjects: Results of the Epidemiology of Vascular Aging Study. Diabetes Care 2001; 24: 366-370.
47. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332.
48. Haan MN, Mungas DM, González HM, Jagust WJ. Prevalence of dementia in older Mexican Americans: the influence of type 2 diabetes, stroke and genetic factors. In Press JAGS 2003.
49. Joshua W Miller, Ralph Green, Marisa I Ramos, Lindsay H Allen, Dan M Mungas, William J Jagust and Mary N Haan. Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging. American Journal of Clinical Nutrition 2003; 78: 441-447.
50. Finch CE, Longo V, Miyao A i wsp. Inflammation in Alzheimer's disease. Contemporary Clinical Neuro-Science. Molecular Mechanisms of Neurodegenerative Disease. MF Chesselet Humana Press Inc. Totowa. NJ 2000.